IP Library Granted Patent US 7,351,801
Granted Patent B2
US 7,351,801 · App. 10/514,544 · Granted Apr 1, 2008

Method, use and kit for separating albumin from contaminants in a liquid

Assignee: GE Healthcare Bio-Sciences AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,351,801
App. No.
10/514,544
Granted
Apr 1, 2008
Kind
B2
Abstract

The present invention is a method of separating recombinant human serum albumin (rHSA) from low molecular weight contaminants in a liquid, which method comprises the steps of: (a) providing a separation medium, which includes anion-exchanging ligands coupled to a base matrix; and (b) contacting the liquid with the separation medium to adsorb the rHSA to the ligands. In one embodiment, the functional groups of the ligands are weak anion-exchanging groups, preferably secondary amines, and the density of ligands on the base matrix is relatively high.

Claims (12)

1. A method of separating recombinant human serum albumin (rHSA) from low molecular weight rHSA degradation products in a liquid, which method comprises the step of

(a) providing a weak anion-exchange separation medium on a base matrix suitable for separating rHSA from said low molecular weight rHSA degradation products;

(b) contacting the liquid containing said rHSA and low molecular weight rHSA degradation products with the separation medium under conditions that allow the rHSA to adsorb and the degradation products to wash through; and

(c) eluting said rHSA from the separation medium using a salt gradient that releases said rHSA from the ligands.

2. The method of claim 1 , wherein the weak anion-exchange separation medium has ligands with the formula:

—O—CH 2 —CH(OH)—CH 2 —O—CH 2 —CH (OH)—CH 2 —N—(CH 2 ) n

where n is an integer of 1-8.

3. The method of claim 1 , wherein the weak anion-exchange separation medium has a ligand concentration of at least about 50 μmol/ml medium.

4. The method of claim 1 , wherein the base matrix includes porous, essentially spherical polysaccharide particles.

5. The method of claim 1 , wherein the low molecular weight degradation products are of a molecular weight below 67 kDa.

6. The method of claim 1 , further comprising an additional step of washing the separation medium with a buffer between steps (b) and (c).

7. The method of claim 1 , wherein the liquid is a culture broth.

Assignments (2)
CHANGE OF NAME Recorded Feb 21, 2006
From: PHARMACIA FINE CHEMICALS AB; PHARMACIA LKB BIOTECHNOLOGY AB; PHARMACIA BIOTECH AB; APBIOTECH AB; AMERSHAM PHARMACIA BIOTECH AB; AMERSHAM BIOSCIENCES AB
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 017186/0644 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2004
From: BELEW, MAKONNEN
To: AMERSHAM BIOSCIENCES AB
Reel/Frame 015397/0675 →
Priority Claims (1)
SE 0201518 · May 15, 2002 · national
Continuity (1)
Related Publication 20050215765A1 · Sep 29, 2005